Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: an open-label phase 2a proof-of-concept studyPeter Connick, Siddharthan Chandran, Ming‐Qing Du et al.|The Lancet Neurology|2012Cited by 606
The mesenchymal stem cells in multiple sclerosis (MSCIMS) trial protocol and baseline cohort characteristics: an open-label pre-test: post-test study with blinded outcome assessmentsPeter Connick, Siddharthan Chandran, Madhan Kolappan et al.|Trials|2011Cited by 119
Assessing structure and function of the afferent visual pathway in multiple sclerosis and associated optic neuritisMadhan Kolappan, D. H. Miller, Thomas M. Jenkins et al.|Journal of Neurology|2009Cited by 109